Ablative radiotherapy improves survival but does not cure autochthonous mouse models of prostate and colorectal cancer.

ABSTRACT:

Background

Genetically engineered mouse models (GEMMs) of cancer are powerful tools to study mechanisms of disease progression and therapy response, yet little is known about how these models respond to multimodality therapy used in patients. Radiation therapy (RT) is frequently used to treat localized cancers with curative intent, delay progression of oligometastases, and palliate symptoms of metastatic disease.

Methods

Here we report the development, testing, and validation of a platform to immobilize and target tumors in mice with stereotactic ablative RT (SART). Xenograft and autochthonous tumor models were treated with hypofractionated ablative doses of radiotherapy.

Results

We demonstrate that hypofractionated regimens used in clinical practice can be effectivel

SUBMITTER: Schmidt DR 

PROVIDER: S-EPMC10412558 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature